Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Hepion Pharmaceuticals, Inc. (CTRV) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Hepion Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1583771.
Total stock buying since 2015: $275,404.
Total stock sales since 2015: $0.
Total stock option exercises since 2015: $24,999.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 11,200 | $49,684 | 0 | $0 | 0 | $0 |
| 2021 | 40,000 | $82,000 | 0 | $0 | 0 | $0 |
| 2020 | 68,500 | $115,545 | 0 | $0 | 0 | $0 |
| 2017 | 20,000 | $13,000 | 0 | $0 | 0 | $0 |
| 2016 | 10,000 | $10,000 | 0 | $0 | 16,666 | $24,999 |
| 2015 | 3,000 | $5,175 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-11 | 5,000 | $15,350 | 0 | $0 | 0 | $0 |
| 2023-09 | 6,200 | $34,334 | 0 | $0 | 0 | $0 |
| 2021-02 | 40,000 | $82,000 | 0 | $0 | 0 | $0 |
| 2020-12 | 64,000 | $108,255 | 0 | $0 | 0 | $0 |
| 2020-11 | 4,500 | $7,290 | 0 | $0 | 0 | $0 |
| 2017-06 | 20,000 | $13,000 | 0 | $0 | 0 | $0 |
| 2016-10 | 0 | $0 | 0 | $0 | 16,666 | $24,999 |
| 2016-02 | 10,000 | $10,000 | 0 | $0 | 0 | $0 |
| 2015-11 | 3,000 | $5,175 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-11-27 | Wijngaard Peter | Buy | 2,500 | 3.05 | 7,625 |
| 2023-11-24 | Wijngaard Peter | Buy | 2,500 | 3.09 | 7,725 |
| 2023-09-19 | Wijngaard Peter | Buy | 1,000 | 5.64 | 5,640 |
| 2023-09-18 | Foster Robert T (CEO and Director) | Buy | 1,600 | 5.60 | 8,960 |
| 2023-09-15 | Wijngaard Peter | Buy | 2,000 | 5.55 | 11,094 |
| 2023-09-15 | Foster Robert T (CEO,CSO and Director) | Buy | 1,600 | 5.40 | 8,640 |
| 2021-02-18 | Foster Robert T (CEO and Director) | Buy | 20,000 | 2.00 | 40,000 |
| 2021-02-18 | Cavan John T (Chief Financial Officer) | Buy | 10,000 | 2.00 | 20,000 |
| 2021-02-16 | Wijngaard Peter | Buy | 10,000 | 2.20 | 22,000 |
| 2020-12-18 | Wijngaard Peter | Buy | 20,000 | 1.91 | 38,200 |
| 2020-12-08 | Foster Robert T (CEO and Director) | Buy | 25,000 | 1.58 | 39,425 |
| 2020-12-02 | Brancaccio John P (Director) | Buy | 7,000 | 1.53 | 10,710 |
| 2020-12-01 | Jacob Gary S (Director) | Buy | 12,000 | 1.66 | 19,920 |
| 2020-11-25 | Cavan John T (Chief Financial Officer) | Buy | 4,500 | 1.62 | 7,290 |
| 2017-06-20 | Cavan John T (CFO) | Buy | 20,000 | .65 | 13,000 |
| 2016-10-27 | Sapirstein James (Chief Executive Officer) | Option Ex | 16,666 | 1.50 | 24,999 |
| 2016-02-18 | Sapirstein James (Chief Executive Officer) | Buy | 10,000 | 1.00 | 10,000 |
| 2015-11-30 | Sapirstein James (Chief Executive Officer) | Buy | 500 | 2.15 | 1,075 |
| 2015-11-23 | Sapirstein James (Chief Executive Officer) | Buy | 2,500 | 1.64 | 4,100 |
Insider trading activities including stock purchases, stock sales, and option exercises of CTRV listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Hepion Pharmaceuticals, Inc. (symbol CTRV, CIK number 1583771) see the Securities and Exchange Commission (SEC) website.